Sabrina Mattoli, M.D., Ph.D.

 

 

Biography

EDUCATION

Medical doctor diploma (summa cum laude) from the University of Perugia (Italy); thesis on the role of calcium ion channels in the pathogenesis of asthma. Specialty diploma (summa cum laude) in pulmonary medicine and tisiology from the Università Cattolica (Italy). Postgraduate research training at the Università Cattolica (Italy) and at the McMaster University (Ontario, Canada).  

PROFESSIONAL EXPERIENCE

Extensive clinical experience as board-certified pulmonologist, with over 18 years of specialty practice. Scientist with consolidated expertise in discovery research and in clinical and translational pulmonology. Entrepreneur with more than 20 years of working experience in the biopharmaceutical sector and a track record of success.  

Founder of the International network for the Advancement of Viable and Applicable Innovations in Life sciences (InAVAIL), which allows R&D-performing organizations, R&D consulting firms and service providers to work to common aims and to accelerate the development of market-creating innovations or reach new markets by sharing innovative methodologies, data, infrastructures, and resources, and by building alliances. Owner of the company Sabrina Mattoli Consulting, with business activities in Basel (Switzerland) and Brussels (Belgium). Expert in Research and Innovation for the European Commission and other public research funding bodies. Eurostars-Eureka scientific and technical expert. Formerly, founder and director of the Swiss company AVAIL GmbH and founder and scientific director of the associated R&D-performing organization Avail Biomedical Research Institute (1998-2017), co-founder and scientific director of the university-affiliated (then university-integrated) research institution Fondazione Italiana di Medicina Sperimentale (FIMS, 1994-1997). Previous experience in internationally accredited academic centers and in other pharmaceutical companies, with leadership positions combining scientific and medical specialty skills or requiring the ability to build multidisciplinary teams of experts for the conduction of translational or clinical research projects. Collaboration with academic institutions and various professional associations in the development of continuing education programs and training courses in pharmacology and pulmonary medicine.

ACHIEVEMENTS

Development of innovative approaches to major challenges in biomedical research and contribution to turn research results into market-creating innovations since the early nineties. Discovery of molecular and cellular pathways implicated in the pathogenesis of asthma. Identification of novel biomarkers of asthma severity and treatment outcome. Development of in-vitro and in-vivo models for the investigation of new therapeutic targets and for testing drug candidates. Identification of the physiological function and therapeutic potential of the fibrocytes (bone marrow-derived mesenchymal progenitors) in tissue repair. Invention of methods for producing stem cell-derived airway epithelial progenitor cells with regenerative potential. Isolation and characterization of stem cell-derived biologics with therapeutic potential in pulmonary fibroses and end-stage pulmonary diseases, which currently require lung transplantation. Set up, growth and international expansions of businesses in the biopharmaceutical research and non-research commercial sectors. Effective long-term collaborations or partnership with diverse start-ups and larger biopharmaceutical companies to accelerate the development and commercialization of 2 novel diagnostics and 9 therapeutic candidates, also including one of the most innovative dermal regeneration scaffold providing controlled release of fibrocyte-derived exosomes and exosomal microRNAs for the repair of diabetic ulcers. Contribution to the establishment of DreiRosen Pharma and to the achievement of its business goals by technology development partnership and strategic advice until acquisition by a clinical-stage biopharmaceutical firm. Contribution to the development of the first device for protection against the deleterious effects of inhaled pollutants (including allergens and cigarette smoke). Demonstration of the unreliability of available methods for monitoring and controlling air pollution at construction and demolition sites, with the in-progress research of innovative solutions.  

Author of over 90 full-length articles, published in peer-reviewed journals, including basic and clinical research articles, editorials and review papers. Author of 9 book chapters and more than 160 published conference abstracts. Consulting editor, member of the editorial board or ad-hoc referee for several scholarly journals. 

Recipient of a Top 10 Special Fellow-in-Training Award of the American Academy of Allergy and Immunology, a Medical Research Council of Canada Fellowship Award, the 1990 Pharmacia Allergy Research Foundation Honourable Mention for Progress in Research, and the 1990 Scientific Award for Excellence in Research of the XIII World Congress of Asthmology. In 1999, listed in the "Outstanding People of the 20th Century" for outstanding contribution to biomedical research, and biography inclusion in "Who's Who in the World", "Who's Who in Medicine and Healthcare" and "Who's Who in Finance and Industry". Recipient of the Top Reviewer Award for exceptional contribution to the quality of the Journal of Immunological Methods in the years 2009-2010. Recipient of the 2018 International Medical Innovation Award for outstanding achievements in regenerative medicine. Co-recipient of the 2021 Healthcare Analytics & Data Science Technology Prize for evaluating the impact on healthcare spending of the implementation of laboratory quality management systems on the basis of the results of EU-funded international surveys. Invited speaker in several scientific sections, symposia and postgraduate courses of international congresses organized by professional associations and major conference producers in the biomedical and pharmaceutical sectors, such as the American Thoracic Society, the British Thoracic Society, the European Tissue Repair Society, Oxford Global, and GTCbio.

View citations of my full-length publications and the h-index in the major core collections of peer-reviewed and high-quality scholarly journals, such as Scopus, Orcid and Web of Science

Read one of my latest review articles on emerging biomarkers of asthma control and therapeutic responsiveness.

Read and share my latest co-authored article on the investigational use of mesenchymal stem/stromal cells and their secretome as add-on therapy in severe respiratory virus infections.

Follow me on LinkedIn.

 

 
 

 

 

 

 

 

 

Contact